StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) income statement

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.87−0.03 (-3.03%)

Close on Nov 18, 2026Market cap $50.90MP/E 21.8Yield –

Spero Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
12.8%
Net margin
15.7%
Return on equity, FY2025
16.3%

Financial strength

Current ratio
6.12
Debt to equity
–
Debt to assets
–
Cash to current liabilities
602.4%

Valuation

P/E ratio
21.8
Price to sales
1.08
Price to book
1.15
Dividend yield
–

See a number that looks wrong?